Isoptin (Verapamil Hydrochloride)

Verapamil blocks L‑type calcium channels on cardiac and smooth‑muscle cells, reducing calcium entry. This decreases heart muscle contractility, slows atrioventricular nodal conduction, and dilates peripheral arteries, which together lower blood pressure, relieve angina, and stabilize abnormal heart rhythms.

The appropriate dose of Isoptin is determined by the prescribing clinician based on the patient’s condition, response, and clinical guidelines. Dosage may vary for hypertension, angina, or arrhythmia management and should be individualized.

Safety data for verapamil during pregnancy and lactation are limited. Healthcare providers should weigh potential benefits against risks and consider alternative therapies when possible. Women who are pregnant, planning pregnancy, or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the Isoptin product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isoptin (verapamil) is a non‑dihydropyridine calcium channel blocker, distinguished by its pronounced effects on cardiac conduction and contractility. Compared with dihydropyridine agents such as amlodipine, verapamil more strongly reduces heart rate and AV nodal transmission, making it useful for arrhythmia control but requiring careful monitoring for bradycardia.

Isoptin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture, direct sunlight and extreme temperature fluctuations to maintain stability.

Isoptin is supplied as a sterile injectable solution for intravenous administration. It is typically infused over a prescribed period under medical supervision, with dosing adjustments made according to the patient’s blood pressure, heart rate and clinical response.

Serious risks include severe hypotension, pronounced bradycardia, atrioventricular block, worsening heart failure, and rare allergic reactions. Patients should be monitored closely for these events, especially during initial dosing or when combined with other heart‑affecting medications.

Isoptin is contraindicated in patients with known hypersensitivity to verapamil, severe hypotension, advanced heart block without a pacemaker, and certain forms of cardiogenic shock. Caution is also advised for individuals with severe hepatic impairment or uncontrolled heart failure.